Latest / The Buyout Show with Fexingo: Private Equity, Roll-Ups, and Business Acquisitions / How Private Equity Consolidates Independent Pharmacies
Transcript
- Lucas: If you walk into any suburban strip mall today, the visual landscape of community pharmacy is shifting faster than most people realize. We are looking at a market where roughly forty percent of independent pharmacies have been acquired by private equity-backed entities over the last five years, a number that feels abstract until you see the actual storefronts changing hands. Luna: It’s not just about buying buildings; it’s about controlling the supply chain and the reimbursement rates. Have you seen the latest data on how this consolidation impacts the average customer's out-of-pocket cost? Lucas: That is the critical question, and the answer is nuanced because while generic prices might look stable on paper, the real story is in the dispensing fees and the service model. Major firms like AmerisourceBergen and McKesson have expanded their purchasing groups, which are essentially consolidated buying clubs that leverage volume to negotiate better rebates from manufacturers. Luna: So the independents aren't just losing their brand identity; they're losing their negotiating power against the very wholesalers they depend on for inventory. Lucas: Exactly. When you merge twenty small pharmacies into one regional entity, you gain administrative efficiency but you also centralize risk. In September 2026, we are seeing a new wave of these deals focused on specialty pharmacies, which handle complex medications for conditions like oncology or rare diseases, rather than just the everyday aspirin and antibiotics. Luna: Specialty care requires more staffing and deeper expertise. Does that mean the local pharmacist becomes more of a technician rather than a clinical advisor? Lucas: That is a genuine concern among healthcare advocates, and the data supports the worry. As operational costs rise due to regulatory compliance and labor shortages, the time spent per patient drops. A study released earlier this year showed that pharmacists in consolidated chains spend an average of four minutes less per consultation than those in truly independent practices. Luna: Four minutes is the difference between catching a dangerous drug interaction and missing it entirely. It seems like efficiency is being prioritized over safety nets. Lucas: Efficiency drives the return on equity for the investors, yes. But let us look at the financial mechanics of why this is happening now. The primary driver is not just economies of scale in buying drugs; it is the ability to standardize billing and reduce overhead through centralized technology platforms. Luna: So the tech stack becomes the moat. Once a pharmacy adopts a specific management software suite tied to a larger network, switching costs become prohibitive for the owner. Lucas: Precisely. And this creates a lock-in effect. Many independent owners sold because they could not afford the constant upgrades required to stay compliant with state laws and insurance mandates. The buyout often includes a transition period where the new parent company absorbs some of those initial costs, making the offer attractive despite the long-term loss of autonomy. Luna: It reminds me of the restaurant industry consolidation. You get the convenience and consistency, but you lose the unique character that made the place worth visiting in the first place. Lucas: The analogy holds, but healthcare is more regulated and less discretionary. People cannot choose a different provider for their insulin just because they prefer a local vibe. This lack of consumer mobility gives the consolidators immense pricing power. Luna: Which brings us back to the patient. If the local pharmacy is no longer independent, who advocates for the patient when there is a formulary change or a price hike? Lucas: That advocacy function is increasingly outsourced to third-party administrators or managed remotely by centralized teams. The face to face relationship, which was the traditional value proposition of the neighborhood pharmacist, is being digitized or eliminated entirely. Luna: It sounds like a classic extractive growth model. Maximize short-term cash flow through cost-cutting and operational standardization, then exit or hold for steady dividends. Lucas: That is the PE playbook, and it works well until external pressures mount. Right now, those pressures are coming from two directions: rising interest rates affecting refinancing costs, and increasing scrutiny from state attorneys general regarding anti-competitive practices. Luna: Are states actually stepping in, or is it mostly talk? Because if regulation doesn't bite, the consolidation will continue unabated. Lucas: We are seeing actual enforcement actions. Several states have launched investigations into whether certain purchasing agreements violate antitrust laws by effectively fixing wholesale prices. This adds legal uncertainty, which tends to slow down deal velocity in the short term. Luna: Uncertainty is good for sellers, I suppose. It gives them leverage to negotiate better terms or walk away from bad deals. Lucas: It does. And we are noticing that some veteran owners are holding firm, waiting for the market to cool before selling. They know their patient base is loyal, and loyalty has a residual value that buyers are eager to capture. Luna: But loyalty only lasts so long if the service deteriorates. If my local pharmacist stops knowing my name, I will switch providers regardless of convenience. Lucas: You might switch, but the barrier to entry for a new competitor is incredibly high. New licenses are restricted in many jurisdictions, and the capital required to build a compliant pharmacy is substantial. This protects the incumbents, even the consolidated ones, from disruption. Luna: So it becomes a duopoly or oligopoly situation. Three or four big players controlling the vast majority of the market, with tiny fragments left for true independents. Lucas: That fragmentation is shrinking rapidly. What used to be fifty percent independent is now closer to thirty-five percent, and that gap is widening every quarter. Luna: This feels like a tipping point. At what percentage does the market lose its competitive dynamics entirely? Lucas: Economists usually flag anything above seventy percent concentration as highly oligopolistic. We are approaching that threshold in several key metropolitan areas, particularly in the Midwest and Southeast. Luna: And the consumers bear the cost. Not just in dollars, but in trust. Healthcare relies on trust, and trust is hard to scale. Lucas: Trust is the hardest asset to quantify on a balance sheet, yet it is the most valuable. When you sell your pharmacy, you are selling that trust to a corporate entity that measures it in churn rates and retention metrics. Luna: It makes you wonder if there is a counter-movement forming. Are there models that resist this consolidation? Lucas: There are cooperative models emerging, where independent pharmacies band together to form their own purchasing alliances without giving up equity. It is slower and less glamorous than a PE buyout, but it preserves autonomy. Luna: Cooperation instead of acquisition. That sounds like a sustainable alternative, provided the members can agree on standards and pricing. Lucas: Agreement is the hard part. Human nature favors conflict, but economic necessity forces alignment. We may see more of these cooperatives as the cost of going solo becomes untenable. Luna: If today was actually useful to you, the way these stay ad-free is listener support — buy me a coffee dot com slash fexingo. Lucas: Your support directly funds the research behind these deep dives. Thank you for keeping the signal strong. Luna: It helps us keep digging into the structural shifts that matter. Lucas: Let us circle back to the cooperatives for a moment. Do you think they can achieve the same economies of scale as the private equity giants? Luna: Unlikely to match them fully, but they don't need to. They just need to be efficient enough to survive and profitable enough to retain independence. Lucas: Survival is the new victory condition in this sector. Growth is secondary to resilience. Luna: Resilience through diversification and shared resources. It is a more organic form of scaling. Lucas: Organic scaling takes longer, but the roots go deeper. Maybe that is the lesson here: speed of acquisition does not equal strength of position. Luna: Or maybe it just means the market is correcting toward stability after a period of speculative excess. Lucas: Whatever the label, the landscape is fundamentally altered. The question is whether we accept that change or fight to preserve the old model. Luna: Preserving the old model might mean preserving inefficiencies. Perhaps the goal should be hybrid efficiency with human-centric values. Lucas: A hybrid model is difficult to define, but easy to recognize when you see it. It requires intentional design, not just market forces. Luna: Intentional design beats passive acceptance every time. Especially in healthcare. Lucas: Agreed. So as we look ahead to the next quarter, watch for those cooperative structures. They might be the quiet counter-weight to the roll-up machine. Luna: They are already starting to appear. Keep an eye on the regional networks forming in rural areas. Lucas: Rural areas are ground zero for this battle. Access is scarce, and competition is non-existent. Luna: Which makes them prime targets for both consolidation and cooperative rescue efforts. Lucas: Two paths diverging in a yellow wood, metaphorically speaking. One paved by capital, the other by collaboration. Luna: And the patients are walking down both, hoping the road leads somewhere safe. Lucas: Safe is a relative term in business. Sustainable is the goal we should all be aiming for.